Insmed met 'much more meaningful' secondary endpoint, says Piper Jaffray Piper Jaffray says Insmed's Phase 2 Study of Arikayce for nontuberculous mycobacteria met the "much more meaningful and clinically relevant" secondary endpoint of culture conversion while missing the less clinically relevant primary endpoint of sputum density. Piper says the drug works and thinks the stock could end up staying close to where it is currently given the split decision on endpoints. The firm reiterates an Overweight rating on Insmed.
News For INSM From The Last 14 Days
Check below for free stories on INSM the last two weeks.